I am a hematologic oncologist who cares for people with lymphoma, including non-Hodgkin lymphoma. I have a particular focus on Hodgkin lymphoma, systemic T cell lymphoma, and cutaneous T cell lymphoma (a rare type of skin lymphoma).
I have been at Memorial Sloan Kettering for more than 11 years. I am part of a team of lymphoma experts who are committed not only to providing world-class care but also to finding newer and better ways to treat these diseases.
Hodgkin lymphoma is a relatively rare disease, but because of treatment advances, we can often cure it. By incorporating newer drugs into our current standard treatments, we can study how patients tolerate their treatment for Hodgkin lymphoma and can lessen the drugs’ long-term negative effects on the body.
T cell lymphoma is rare and can be challenging to treat. Our clinical trials in T cell lymphoma are testing targeted therapies and immunotherapies aimed at improving our ability to control the disease and patients’ quality of life — as well as the chance of a cure.
When I see patients for the first time, my goal is that they leave the appointment with a clear understanding of their diagnosis and treatment options, as well as the many resources available at MSK to help them cope with their treatment. I am fortunate to work with a team of nurses, social workers, and clinical assistants who create a comforting and supportive environment for our patients. While I understand that it is very scary for people to be told they have cancer, it is important to me that I help make the experience less scary and work with my patients so they feel as well as possible.
- Clinical Expertise: Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Cutaneous T Cell Lymphoma
- Languages Spoken: English
- Education: MD, Albert Einstein College of Medicine
- Residencies: Internal Medicine - Columbia University Medical Center
- Fellowships: Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
- Board Certifications: Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Alison J. Moskowitz
- A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
- A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Hodgkin Lymphoma
- A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
- A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
Clinical Trials Co-Investigated by Alison J. Moskowitz
- A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
- A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
- A Phase I Study of Hu5F9-G4 Immunotherapy in Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
- A Phase I/II Study of Lenalidomide plus Combination Chemotherapy to Treat Newly Diagnosed Stage II-IV Peripheral T-Cell Lymphoma
- A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
- A Phase III Study of Brentuximab Vedotin plus CHP versus CHOP Therapy for Patients with Previously Untreated CD30-Positive Peripheral T-Cell Lymphoma
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more